Maravai LifeSciences Holdings, Inc.
MRVI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1 | $2 | $4 | $9 |
| - Cash | $0 | $1 | $1 | $1 |
| + Debt | $0 | $1 | $1 | $1 |
| Enterprise Value | $1 | $2 | $4 | $9 |
| Revenue | $0 | $0 | $1 | $1 |
| % Growth | -10.3% | -67.3% | 10.5% | – |
| Gross Profit | $0 | $0 | $1 | $1 |
| % Margin | 41.8% | 48.5% | 80.9% | 82.4% |
| EBITDA | -$0 | $1 | $1 | $1 |
| % Margin | -60.5% | 246.6% | 69.1% | 73.3% |
| Net Income | -$0 | -$0 | $0 | $0 |
| % Margin | -55.9% | -41.2% | 24.9% | 22.8% |
| EPS Diluted | -1.05 | -0.9 | 1.67 | 1.56 |
| % Growth | -16.7% | -153.9% | 7.1% | – |
| Operating Cash Flow | $0 | $0 | $1 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | $0 | $1 | $0 |